This safety aspect, as it pertains not only to on-target, on-tumor toxicity but also on-target, off-tumor toxicity, may be particularly important for a myeloid differentiation antigen such as CD33 that is broadly expressed not only on AML cells but also on normal maturing and mature myeloid cells [10,11]. This evidence concerns the gene CD33 and acute myeloid leukemia.